Bibliothèque

Conversion surgical after neoadjuvant immunochemotherapy achieves survival comparable to initially resectable disease in borderline resectable esophageal cancer.

BACKGROUND: Immune checkpoint inhibitors have demonstrated preliminary safety and efficacy in treating borderline resectable esophageal squamous cell carcinoma (BR-ESCC). We aimed to compare treatment…

Thérapies de Conversion

Xu, B., Wang, H., Zhang, C., Luo, T., Xiong, J., Ran, X., Liu, J., Shi, G., & Fu, M. (2026). Conversion surgical after neoadjuvant immunochemotherapy achieves survival comparable to initially resectable disease in borderline resectable esophageal cancer.. Int J Clin Oncol, 31(6), 1017-1025. https://doi.org/10.1007/s10147-026-03018-x

01/06/2026 Lire →

Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

BACKGROUND: Malignant hepatocellular neoplasm, not otherwise specified (HCN, NOS), is a rare primary liver tumor showing overlapping features of hepatoblastoma and hepatocellular carcinoma. Because of…

Thérapies de Conversion

Moriyama, E., Koga, H., Niizeki, T., Iwamoto, H., Shimose, S., Shirono, T., Tokushige, T., Nakano, M., Kuromatsu, R., Goto, T., Honda, M., Hibi, T., Mikami, Y., Kondo, R., Akiba, J., & Kawaguchi, T. (2026). Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.. Hepatol Res, 56(6), 1047-1052. https://doi.org/10.1111/hepr.70142

01/06/2026 Lire →

Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: effects on tumor necrosis and anti-tumor immune response.

PURPOSE: We analyzed the clinical efficacy and safety of conversion therapy for unresectable hepatocellular carcinoma (uHCC) using transarterial chemoembolization (TACE) plus tislelizumab and characte…

Thérapies de Conversion

Yao, Q., Chen, G., Yu, Y., Chen, Z., An, X., Xie, X., Wang, Q., Chen, D., & Sun, H. (2026). Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: effects on tumor necrosis and anti-tumor immune response.. Clin Transl Oncol, 28(6), 2208-2218. https://doi.org/10.1007/s12094-025-04159-7

01/06/2026 Lire →

An Unconscionable Decision.

Thérapies de Conversion

Swartz, H. A. (2026). An Unconscionable Decision.. Am J Psychother, 79(2), 47-48. https://doi.org/10.1176/appi.psychotherapy.20260023

01/06/2026 Lire →

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

BACKGROUND: A significant portion of primary liver cancer patients in China are diagnosed at intermediate-to-advanced stages, often making them ineligible for curative surgery. Furthermore, high posto…

Thérapies de Conversion

Wang, Z., Sun, H., Zhou, J., Xie, Q., Bi, X., Liu, X., Liu, R., Zhao, M., Bai, X., Ji, Y., Xu, L., Jia, W., Zeng, S., Li, G., Zhang, W., Shen, S., Rao, S., Shi, G., Zhang, L., … Alliance, o. f. . L. i. v. e. r. . C. a. n. c. e. r. . C. o. n. v. e. r. s. i. o. n. . T. h. e. r. a. p. y. ,. . L. i. v. e. r. . C. a. n. c. e. r. . C. o. m. m. i. t. t. e. e. ,. . C. h. i. n. a. . A. n. t. i. -. C. a. n. c. e. r. . A. s. s. o. c. i. a. t. i. o. n. (2026). Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).. Hepatobiliary Surg Nutr, 15(3), 72. https://doi.org/10.21037/hbsn-2025-129

01/06/2026 Lire →

Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma.

BACKGROUND AND AIMS: To evaluate the prognostic significance of pathological response in patients with initially unresectable hepatocellular carcinoma (uHCC) who underwent salvage resection after succ…

Thérapies de Conversion

Chi, Q. Y., Gao, X. D., Wang, M., Liu, Q. Y., Zeng, Y. Y., Yang, L. F., Liu, Z. J., Wang, S. J., Weng, S. G., & Zhang, Z. B. (2026). Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma.. Liver Int, 46(6), e70681. https://doi.org/10.1111/liv.70681

01/06/2026 Lire →

"Conversion Therapy" in the US-Progress, Missed Opportunities, and Future Directions.

Thérapies de Conversion

Gavulic, K. A., Pachankis, J. E., & Aaron, D. G. (2026). "Conversion Therapy" in the US-Progress, Missed Opportunities, and Future Directions.. JAMA Pediatr, 180(6), 599-600. https://doi.org/10.1001/jamapediatrics.2026.0394

01/06/2026 Lire →

[Precise prevention and treatment strategies for surgical complications after conversion therapy for gastric cancer].

Conversion therapy offers a potential curative opportunity for patients with initially unresectable gastric cancer. However, the consequent systemic and local pathophysiological changes significantly …

Thérapies de Conversion

Zhou, Y. B. (2026). [Precise prevention and treatment strategies for surgical complications after conversion therapy for gastric cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 621-626. https://doi.org/10.3760/cma.j.cn441530-20260302-00105

25/05/2026 Lire →

[Conversion surgery strategy for adenocarcinoma of the esophagogastric junction].

The incidence of adenocarcinoma of the esophagogastric junction (AEG) continues to rise, with 20%-30% of patients initially diagnosed with stage IV disease, for whom conventional palliative treatment …

Thérapies de Conversion

Hu, W. Q., Peng, W., & Song, D. Y. (2026). [Conversion surgery strategy for adenocarcinoma of the esophagogastric junction].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 608-614. https://doi.org/10.3760/cma.j.cn441530-20260228-00101

25/05/2026 Lire →

[Innovation in the treatment paradigm for advanced-stage colorectal cancer: new strategies and future directions].

The treatment model for colorectal cancer has undergone a significant evolution, progressing from single surgical resection to multidisciplinary team (MDT)-based comprehensive therapy. As a revolution…

Thérapies de Conversion

Wei, J. S., Hu, H. G., Wang, J., & Ding, K. F. (2026). [Innovation in the treatment paradigm for advanced-stage colorectal cancer: new strategies and future directions].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 601-607. https://doi.org/10.3760/cma.j.cn441530-20260212-00085

25/05/2026 Lire →

[Expert consensus on the clinical application of the Chinese-modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil / leucovorin for colorectal cancer (2026 edition)].

Chemotherapy is the cornerstone of colorectal cancer treatment, especially for microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer. The FOLFOXIRI triplet regimen (fluorouraci…

Thérapies de Conversion

Committee, o. f. . C. o. l. o. r. e. c. t. a. l. . C. a. n. c. e. r. ,. . C. h. i. n. a. . S. o. u. t. h. w. e. s. t. . O. n. c. o. l. o. g. y. . G. r. o. u. p. (2026). [Expert consensus on the clinical application of the Chinese-modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil / leucovorin for colorectal cancer (2026 edition)].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 573-584. https://doi.org/10.3760/cma.j.cn441530-20260227-00099

25/05/2026 Lire →

[Chinese expert consensus on the management of immune-related adverse events associated with perioperative immunotherapy for gastrointestinal tumors (2026 edition)].

In recent years,immunotherapy has made breakthrough progress in the perioperative treatment of gastrointestinal tumors. Immunotherapy could improve pathologic response rates and long-term survival,but…

Thérapies de Conversion

Committee, f. o. r. . S. u. r. g. i. c. a. l. . S. a. f. e. t. y. . a. n. d. . Q. u. a. l. i. t. y. . C. o. n. t. r. o. l. ,. C. h. i. n. e. s. e. . A. n. t. i. -. C. a. n. c. e. r. . A. s. s. o. c. i. a. t. i. o. n. (2026). [Chinese expert consensus on the management of immune-related adverse events associated with perioperative immunotherapy for gastrointestinal tumors (2026 edition)].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 545-562. https://doi.org/10.3760/cma.j.cn441530-20260307-00114

25/05/2026 Lire →